• 1. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 2. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 3. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544
• 4. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 5. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991

Introduction to Rilpivirine (CAS No: 500287-72-9) in Modern Pharmaceutical Research

Rilpivirine, chemically identified by the CAS number 500287-72-9, is a significant compound in the realm of pharmaceutical chemistry, particularly in the development of antiviral medications. As a non-nucleoside reverse transcriptase inhibitor (NNRTI), Rilpivirine has demonstrated remarkable efficacy in the treatment of HIV-1 infection. Its molecular structure, characterized by a pyrrolidinylpyrimidine core, contributes to its unique mechanism of action, which involves the inhibition of viral replication by binding to the reverse transcriptase enzyme. This interaction prevents the conversion of viral RNA into DNA, thereby halting the spread of the virus within the host.

The pharmacological profile of Rilpivirine has been extensively studied and validated through numerous clinical trials. One of the most notable aspects of its development is its high genetic barrier to resistance, which makes it particularly effective in patients who may have developed resistance to other NNRTIs. This resistance profile is attributed to its specific binding interactions with the reverse transcriptase enzyme, which are less prone to mutation compared to other antiviral agents. The compound's ability to maintain efficacy over prolonged periods has made it a cornerstone in combination therapy regimens for HIV-1 infection.

Recent advancements in drug design and molecular modeling have further illuminated the structural and functional properties of Rilpivirine. These studies have revealed that its pyrrolidinylpyrimidine core interacts with key residues in the reverse transcriptase enzyme, such as Tyr215 and Lys101, which are critical for its inhibitory activity. Understanding these interactions has not only enhanced our comprehension of Rilpivirine's mechanism of action but also provided insights into potential drug optimization strategies. For instance, modifications to its structure could improve pharmacokinetic properties or expand its spectrum of activity against other viral strains.

In clinical settings, Rilpivirine is often administered as part of a fixed-dose combination (FDC) pill, which simplifies dosing and improves patient adherence. The FDC formulation typically includes Rilpivirine along with other antiretroviral drugs, such as emtricitabine and tenofovir disoproxil fumarate (TDF). This combination approach leverages the synergistic effects of multiple drugs, reducing the likelihood of viral resistance and improving therapeutic outcomes. The simplicity and effectiveness of these combination therapies have made them a preferred choice for healthcare providers managing HIV-1 infection.

The safety profile of Rilpivirine has been thoroughly evaluated through extensive clinical trials involving diverse patient populations. Common adverse effects associated with its use include nausea, headache, insomnia, and rash. However, these side effects are generally mild and well-tolerated, making Rilpivirine an attractive option for long-term treatment. Importantly, there are no significant drug-drug interactions reported with commonly used medications for other conditions, further enhancing its clinical applicability.

Emerging research has also explored the potential applications of Rilpivirine beyond HIV-1 treatment. Studies suggest that its mechanism of action may be adaptable to other viral infections caused by reverse transcriptase enzymes. For instance, investigations have examined its efficacy against hepatitis B virus (HBV) and certain strains of human papillomavirus (HPV). While further research is needed to validate these findings, they highlight the broad therapeutic potential of Rilpivirine and related compounds.

The development and optimization of Rilpivirine exemplify the progress made in rational drug design and targeted therapy. By leveraging structural biology and computational methods, researchers have been able to fine-tune the pharmacological properties of this compound to maximize its therapeutic benefit while minimizing side effects. This approach underscores the importance of interdisciplinary collaboration between chemists, biologists, and clinicians in advancing pharmaceutical innovation.

Looking ahead, continued research into Rilpivirine and related NNRTIs will likely uncover new insights into viral replication mechanisms and identify novel therapeutic targets. Additionally, advancements in drug delivery systems may enhance the bioavailability and stability of Rilpivirine, further improving patient outcomes. As part of ongoing efforts to combat infectious diseases, compounds like Rilpivirine will remain essential tools in our arsenal against viruses that pose significant public health challenges.

• 500288-02-8(Benzonitrile,4-[[4-[[4-[(1Z)-2-cyano-1-methylethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]-)
• 500288-43-7(Propanedinitrile,[[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]-)
• 700361-47-3(Rilpivirine Hydrochloride)
• 244767-67-7(Dapivirine)
• 500288-45-9(Benzonitrile,4-[[4-[[2,6-dimethyl-4-[2-(3-pyridinyl)ethenyl]phenyl]amino]-2-pyrimidinyl]amino]-)
• 500287-94-5((1Z)-Rilpivirine)
• 1329613-10-6(Dapivirine-d11)
• 1312424-26-2(Rilpivirine-d6)
• 244767-86-0(Benzonitrile,4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl-)
• 500293-43-6(Benzonitrile,4-[[4-[(3-amino-2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]-)